Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-12-11 Capital/Financing Update
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
4DMedical secures $30.2 million with options underwrite 6 pages 369.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 12 December 2025 by 4DMedical Limited regarding securing $30.2 million in funding through an underwriting agreement for the exercise of listed options. It details the underwriting agreement terms, termination events, and related regulatory compliance under ASX Listing Rules. The content focuses on capital raising and financing activities, including option exercise underwriting and cash balance impact. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a report itself but an announcement of a financing event and related contractual terms. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support a high confidence classification as CAP.
2025-12-11 English
University of Miami adopts CTVQ 2 pages 248.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 10 December 2025 from 4DMedical Limited. It announces the commercial launch and adoption of their CT:VQ™ technology at the University of Miami and a new agreement with Lahey Hospital & Medical Center. The content focuses on commercial arrangements, product adoption, and strategic updates rather than financial results, regulatory filings, or detailed financial reports. There are no financial statements, earnings data, or management discussion of financial results. The document is a corporate announcement about commercial and operational developments, fitting best into the category of Capital/Financing Update (CAP) as it relates to commercial agreements and business development activities. The document length (5941 characters) and content do not indicate it is a report publication announcement or regulatory filing. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2025-12-09 English
4DMedical secures US$10m CTVQ orders in Philips deal 3 pages 271.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 3 December 2025, detailing a commercial agreement between 4DMedical and Philips regarding distribution and sales of a medical imaging product (CT:VQ™). It includes highlights, market opportunity, and an investor webinar invitation. There are no financial statements, regulatory certifications, or detailed financial results presented. The content focuses on a capital/financing update related to a significant commercial contract and revenue visibility from minimum order commitments. The document length is 7703 characters, which is substantial but the content is clearly an announcement of a commercial deal rather than a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-12-02 English
Notification of upcoming expiry of Listed Options 6 pages 1.2MB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from 4DMedical Limited regarding the expiry of listed options exercisable at a specific price by a certain date. It includes detailed instructions for option holders on how to exercise their options, the expiry date, cessation of official quotation of the options, and payment methods. The content is focused on informing shareholders about the option expiry and exercise process, not on financial results, management changes, or other report types. This type of document is a capital/financing update related to the company's capital structure (options exercise and expiry). It is not a full financial report, earnings release, or regulatory filing of another type. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-11-30 English
Application for quotation of securities - 4DX 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, issue price, and the resulting issued capital. This type of document is not a financial report, earnings release, or management discussion but rather an official announcement related to capital changes and securities quotation on the exchange. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not merely a brief announcement but a full application form for quotation of securities.
2025-11-25 English
Application for quotation of securities - 4DX 7 pages 21.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue dates, issue prices, and whether the securities rank equally with existing securities. It does not contain financial statements, management discussion, or earnings data. It is not a report but an announcement related to capital changes, specifically the issuance and quotation of new shares. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a formal application for quotation of securities, consistent with SHA filings.
2025-11-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.